CN1279040C - 用于治疗的莨菪烷衍生物 - Google Patents

用于治疗的莨菪烷衍生物 Download PDF

Info

Publication number
CN1279040C
CN1279040C CNB018088287A CN01808828A CN1279040C CN 1279040 C CN1279040 C CN 1279040C CN B018088287 A CNB018088287 A CN B018088287A CN 01808828 A CN01808828 A CN 01808828A CN 1279040 C CN1279040 C CN 1279040C
Authority
CN
China
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018088287A
Other languages
English (en)
Chinese (zh)
Other versions
CN1437599A (zh
Inventor
M·派洛斯
D·A·普利斯
B·L·C·司塔曼
A·伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CN1437599A publication Critical patent/CN1437599A/zh
Application granted granted Critical
Publication of CN1279040C publication Critical patent/CN1279040C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
CNB018088287A 2000-05-26 2001-05-09 用于治疗的莨菪烷衍生物 Expired - Lifetime CN1279040C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0014046.7 2000-05-26
GB0015835.2 2000-06-27
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNB2005100068151A Division CN100355753C (zh) 2000-05-26 2001-05-09 用于制备具有治疗作用的莨菪烷衍生物的中间体
CN2006100735840A Division CN1830445B (zh) 2000-05-26 2001-05-09 含有具有治疗作用的莨菪烷衍生物的组合物及其多晶型物

Publications (2)

Publication Number Publication Date
CN1437599A CN1437599A (zh) 2003-08-20
CN1279040C true CN1279040C (zh) 2006-10-11

Family

ID=26244452

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018088287A Expired - Lifetime CN1279040C (zh) 2000-05-26 2001-05-09 用于治疗的莨菪烷衍生物
CNB2005100068151A Expired - Lifetime CN100355753C (zh) 2000-05-26 2001-05-09 用于制备具有治疗作用的莨菪烷衍生物的中间体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2005100068151A Expired - Lifetime CN100355753C (zh) 2000-05-26 2001-05-09 用于制备具有治疗作用的莨菪烷衍生物的中间体

Country Status (50)

Country Link
EP (3) EP1990341B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP3693957B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100523501B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN1279040C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP1965A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR028622A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE260914T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU5248201A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG65966B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0110955B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2408909C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR10145A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU (1) CU23288B7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY2008006I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ299102B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE60135685D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1526134T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DZ (1) DZ3464A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (2) EA007580B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE05110B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EG (1) EG24137A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2311126T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR08C0007I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP20063799B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20020938B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU225810B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL152531A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2511B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1284974I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91417I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA26902A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME00555A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA02011631A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (3) MY156920A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300338I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO327892B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ521477A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA12264A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PA (1) PA8517101A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20011371A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL200551B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT1284974E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (2) RS51436B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI1526134T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK286129B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TNSN01077A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200400541T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI230160B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY26727A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2001090106A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007580B1 (ru) * 2000-05-26 2006-12-29 Пфайзер Инк. Комбинация, содержащая производные тропана, полезные в терапии
KR20040007672A (ko) * 2001-06-12 2004-01-24 에스케이 주식회사 신규한 페닐알킬디아민 및 아미드 유사체
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
PL372968A1 (en) * 2002-04-08 2005-08-08 Pfizer Inc. Tropane derivatives as ccr5 modulators
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
MXPA04011577A (es) * 2002-05-23 2005-03-07 Pfizer Metodo para la identificacion de un ligando, por el cual se mide el tiempo de residencia del receptor.
JP2006514646A (ja) * 2002-12-13 2006-05-11 スミスクライン ビーチャム コーポレーション Ｃｃｒ５アンタゴニストとしてのシクロヘキシル化合物類
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
EP1663999A2 (en) 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
RS20060198A (en) * 2003-10-03 2008-09-29 Pfizer Limited, Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activ ity for the treatment of hiv and inflammation
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
PL1761542T3 (pl) 2004-06-09 2008-06-30 Hoffmann La Roche Pochodne oktahydropirolo[3,4-c]pirolu i ich zastosowanie jako środków przeciwwirusowych
EP1814549A2 (en) * 2004-11-19 2007-08-08 Boehringer Ingelheim International GmbH Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
WO2007014114A2 (en) 2005-07-22 2007-02-01 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
KR20090013827A (ko) * 2006-06-12 2009-02-05 화이자 프로덕츠 인크. Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제
BRPI0715193A2 (pt) 2006-08-16 2013-10-01 Hoffmann La Roche inibidores nço-nucleosÍdicos da transcriptase reversa
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
CA2673566A1 (en) * 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
RU2368613C1 (ru) * 2008-02-19 2009-09-27 Институт молекулярной генетики Российской Академии наук (ИМГ РАН) (Статус Государственного учреждения) Равномерно меченный тритием 4,4-дифтор-n-{(1s)-3-[3-(3-изопропил-5-метил-4н-1,2,4-триазол-4-ил)-8-азабицикло[3.2.1]окт-8-ил]-1-фенилпропил}циклогексан карбодиимид
WO2009111218A2 (en) * 2008-02-29 2009-09-11 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
WO2011011652A1 (en) * 2009-07-24 2011-01-27 Glaxosmithkline Llc Therapeutic compounds
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
EP2552429A1 (en) 2010-04-02 2013-02-06 Phivco-1 LLC Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer
CN106977511B (zh) * 2011-12-19 2019-04-12 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
EP2912047B1 (en) 2012-10-29 2016-08-24 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104402883B (zh) * 2014-10-24 2016-04-27 艾琪康医药科技（上海）有限公司 4，4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
PL183025B1 (pl) * 1994-04-19 2002-05-31 Neurosearch As Pochodne tropanu, sposób ich otrzymywania i zawierające je kompozycje
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998002151A2 (en) * 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998025604A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2296314A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
CA2318088A1 (en) * 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
EA007580B1 (ru) * 2000-05-26 2006-12-29 Пфайзер Инк. Комбинация, содержащая производные тропана, полезные в терапии

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
ME00555B (me) 2011-12-20
NO20025227L (no) 2002-10-31
CA2408909C (en) 2006-06-27
BR0110955A (pt) 2003-06-03
ATE260914T1 (de) 2004-03-15
BRPI0110955B8 (pt) 2021-05-25
HK1090836A1 (en) 2007-01-05
LU91417I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-02
MXPA02011631A (es) 2003-03-27
YU82202A (sh) 2005-11-28
NL300338I2 (nl) 2008-06-02
AP2002002663A0 (en) 2002-12-31
JP4854970B2 (ja) 2012-01-18
PL359267A1 (en) 2004-08-23
SK16432002A3 (sk) 2004-01-08
KR20030004417A (ko) 2003-01-14
EE200200656A (et) 2004-06-15
EE05110B1 (et) 2008-12-15
RS50904B (sr) 2010-08-31
LU91417I2 (fr) 2008-04-22
MY156920A (en) 2016-04-15
CZ299102B6 (cs) 2008-04-23
TWI230160B (en) 2005-04-01
NO2010007I1 (no) 2010-04-08
HRP20020938B1 (en) 2011-05-31
ATE407134T1 (de) 2008-09-15
LTPA2008004I1 (lt) 2020-07-27
CU23288B7 (es) 2008-06-30
IL152531A (en) 2010-05-17
CR10145A (es) 2008-08-19
EP1526134A3 (en) 2006-11-29
EP1526134B1 (en) 2008-09-03
WO2001090106A3 (en) 2002-03-28
NO20025227D0 (no) 2002-10-31
HK1054927A1 (en) 2003-12-19
RS20090438A (en) 2010-05-07
JP2003534343A (ja) 2003-11-18
DZ3464A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-11-29
MY131019A (en) 2007-07-31
ES2215129T3 (es) 2004-10-01
NO2010007I2 (no) 2013-09-09
PT1284974E (pt) 2004-06-30
CY2022009I1 (el) 2022-05-27
ES2311126T3 (es) 2009-02-01
PT1526134E (pt) 2008-10-28
CN1680371A (zh) 2005-10-12
TR200400541T4 (tr) 2004-04-21
IL152531A0 (en) 2003-05-29
ME00555A (en) 2011-12-20
LTC1284974I2 (lt) 2020-11-10
EA200201141A1 (ru) 2003-04-24
CY1108451T1 (el) 2014-04-09
ES2401812T3 (es) 2013-04-24
NL300338I1 (nl) 2008-05-01
WO2001090106A2 (en) 2001-11-29
EP1990341A1 (en) 2008-11-12
NO2020019I1 (no) 2020-06-30
HRP20020938A2 (en) 2005-02-28
EP1990341B1 (en) 2013-01-23
KR100548854B1 (ko) 2006-02-02
PA8517101A1 (es) 2002-10-24
AU5248201A (en) 2001-12-03
BG65966B1 (bg) 2010-07-30
TNSN01077A1 (fr) 2005-11-10
NZ521477A (en) 2004-07-30
DE60102233T2 (de) 2005-01-27
AU2001252482C1 (en) 2001-12-03
RS51436B (en) 2011-04-30
BRPI0110955B1 (pt) 2016-06-28
AR028622A1 (es) 2003-05-14
JP2005194283A (ja) 2005-07-21
DE60135685D1 (de) 2008-10-16
DK1284974T3 (da) 2004-06-07
KR20050046743A (ko) 2005-05-18
MA26902A1 (fr) 2004-12-20
KR100523501B1 (ko) 2005-10-25
JP3693957B2 (ja) 2005-09-14
CZ20023806A3 (cs) 2004-01-14
AP1965A (en) 2009-03-04
OA12264A (en) 2003-11-10
CA2408909A1 (en) 2001-11-29
CY2008006I1 (el) 2009-11-04
HUP0302474A2 (hu) 2003-11-28
EA007580B1 (ru) 2006-12-29
IS6565A (is) 2002-09-24
DE122008000011I1 (de) 2008-06-05
NO327892B1 (no) 2009-10-12
EA005382B1 (ru) 2005-02-24
CY2022009I2 (el) 2022-05-27
HK1078573A1 (en) 2006-03-17
SI1526134T1 (sl) 2008-12-31
CY2008006I2 (el) 2009-11-04
DK1526134T3 (da) 2008-11-17
UY26727A1 (es) 2001-12-28
AR060159A2 (es) 2008-05-28
HU225810B1 (en) 2007-10-29
GEP20063799B (en) 2006-04-25
FR08C0007I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2008-04-25
EP1284974B1 (en) 2004-03-03
FR08C0007I2 (fr) 2009-01-15
EG24137A (en) 2008-08-06
EA200401056A1 (ru) 2005-04-28
EP1284974A2 (en) 2003-02-26
CN1437599A (zh) 2003-08-20
PL200551B1 (pl) 2009-01-30
EP1526134A2 (en) 2005-04-27
DE60102233D1 (de) 2004-04-08
SI1284974T1 (en) 2004-08-31
AU2001252482B2 (en) 2006-01-19
HUP0302474A3 (en) 2007-05-29
MY153023A (en) 2014-12-31
IS2511B (is) 2009-05-15
CN100355753C (zh) 2007-12-19
SK286129B6 (sk) 2008-04-07
BG107140A (bg) 2003-05-30
PE20011371A1 (es) 2002-01-18

Similar Documents

Publication Publication Date Title
CN1279040C (zh) 用于治疗的莨菪烷衍生物
CN1324025C (zh) 作为ccr5调节剂的托烷衍生物
CN1252071C (zh) 黄嘌呤磷酸二酯酶v抑制剂
CN1263755C (zh) 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
CN1291986C (zh) 抗胆碱能剂,其制备方法及其作为药物的用途
HK1039902A1 (zh) 用作趨化因子受體5調節劑的氮雜二環烷烴
CN1802159A (zh) 治疗哮喘及其它炎症或免疫性疾病的具有ccr3拮抗活性的2－苯氧基－和2－苯基磺酰胺衍生物
CN1331691A (zh) 作为趋化细胞因子受体5调制剂的哌啶
CN1214339A (zh) 吡唑衍生物、其制备方法和在药物中的应用
CN101068793A (zh) Hiv整合酶抑制剂的钾盐
CN1652779A (zh) 化学激活物中介的疾病的结合治疗
CN1780621A (zh) 作为γ分泌酶抑制剂的磺酰胺衍生物
CN1659147A (zh) 哒嗪衍生物
CN1207731A (zh) 具有大麻素受体亲合力的3-吡唑甲酰胺衍生物
CN1820010A (zh) 作为γ－分泌素酶抑制剂的桥联N－芳基磺酰基哌啶
CN1922175A (zh) 作为5－ht4受体激动剂的吲唑－甲酰胺化合物
CN1826334A (zh) 趋化因子受体活性的四氢吡喃基环戊基杂环酰胺调节剂
CN101048393A (zh) 作为γ－分泌酶抑制剂的取代的N－芳基磺酰基杂环胺
CN1756740A (zh) 具有2,6－二取代苯乙烯基的含氮杂环衍生物
CN1812967A (zh) 组织蛋白酶半胱氨酸蛋白酶抑制剂
CN1875017A (zh) 取代的4－氨基－1－(吡啶基甲基)哌啶化合物的萘－1,5－二磺酸盐
CN101068916A (zh) 阿扎那韦用于改良通过ugt1a1代谢的药物的药物动力学的用途
CN1703410A (zh) 异喹啉化合物及其医药用途
CN1620292A (zh) 含杂环取代苯基的磺酰胺广谱hiv蛋白酶抑制剂
CN1830445A (zh) 含有具有治疗作用的莨菪烷衍生物的组合物及其多晶型物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20061011

CX01 Expiry of patent term